Shenghui Tang Selected Research

Musculoskeletal Pain

1/2020	FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.
8/2017	U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
10/2015	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shenghui Tang Research Topics

Disease

24	Neoplasms (Cancer) 10/2023 - 03/2007
19	Breast Neoplasms (Breast Cancer) 02/2024 - 09/2013
17	Disease Progression 03/2024 - 08/2006
17	Nausea 02/2024 - 01/2012
16	Diarrhea 01/2023 - 12/2006
16	Fatigue 01/2023 - 01/2012
10	Vomiting 02/2024 - 06/2015
10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 01/2010
9	Renal Cell Carcinoma (Grawitz Tumor) 03/2024 - 12/2006
9	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 12/2013
8	Anemia 12/2023 - 10/2015
8	Constipation 01/2023 - 08/2017
8	Hypertension (High Blood Pressure) 01/2023 - 12/2006
8	Neutropenia 01/2020 - 01/2012
7	Alopecia (Baldness) 01/2023 - 09/2013
7	Exanthema (Rash) 01/2022 - 01/2010
6	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 10/2015
6	Headache (Headaches) 11/2022 - 10/2015
5	Arthralgia (Joint Pain) 01/2022 - 10/2014
4	Carcinoma (Carcinomatosis) 03/2024 - 01/2017
4	Abdominal Pain (Pain, Abdominal) 01/2023 - 10/2015
4	Triple Negative Breast Neoplasms 12/2022 - 07/2014
4	Dyspnea (Shortness of Breath) 01/2022 - 08/2017
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 09/2013
3	Myalgia 01/2023 - 10/2015
3	Cough 01/2022 - 10/2015
3	Asthenia 01/2022 - 01/2012
3	Infections 11/2021 - 08/2002
3	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2013
3	Thrombocytopenia (Thrombopenia) 01/2020 - 12/2017
3	Musculoskeletal Pain 01/2020 - 10/2015
3	Dysgeusia (Parageusia) 12/2017 - 03/2007
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2023 - 03/2007
2	Primitive Neuroectodermal Tumors (PNET) 11/2022 - 01/2012
2	Hypoxia (Hypoxemia) 11/2022 - 08/2017
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2022 - 01/2012
2	medullary Thyroid cancer 01/2021 - 07/2012
2	Leukopenia 01/2018 - 11/2015
2	Back Pain (Backache) 01/2018 - 10/2015
2	Mucositis 01/2018 - 03/2007
2	Nasopharyngitis 01/2018 - 10/2015
2	Melanoma (Melanoma, Malignant) 01/2016 - 10/2014
1	Dyslipidemias (Dyslipidemia) 02/2024

Drug/Important Bio-Agent (IBA)

13	PlatinumIBA 10/2023 - 01/2010
9	Hormones (Hormone)IBA 08/2023 - 07/2014
7	ErbB Receptors (EGF Receptor)IBA 02/2024 - 01/2010
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 09/2013
4	Immune Checkpoint InhibitorsIBA 03/2024 - 08/2017
4	Fulvestrant (Faslodex)FDA Link 08/2023 - 01/2020
4	Aromatase InhibitorsIBA 08/2023 - 01/2018
4	atezolizumabIBA 01/2020 - 01/2017
4	TabletsIBA 10/2014 - 01/2010
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 03/2024 - 01/2018
3	pembrolizumabIBA 03/2024 - 01/2019
3	Estrogen ReceptorsIBA 02/2024 - 11/2015
3	olaparibIBA 12/2023 - 10/2015
3	NivolumabIBA 10/2023 - 01/2016
3	taxaneIBA 01/2023 - 01/2020
3	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 01/2021
3	Glucose (Dextrose)FDA LinkGeneric 11/2022 - 06/2015
3	Cyclin-Dependent Kinase 4IBA 11/2021 - 01/2018
3	Lipase (Acid Lipase)FDA Link 01/2021 - 12/2006
3	Alanine Transaminase (SGPT)IBA 01/2021 - 06/2015
3	Docetaxel (Taxotere)FDA Link 11/2015 - 09/2013
2	enzalutamideIBA 03/2024 - 08/2015
2	enfortumab vedotinIBA 03/2024 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 02/2024 - 10/2023
2	B7-H1 AntigenIBA 02/2024 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2017
2	trastuzumab deruxtecanIBA 10/2023 - 01/2021
2	ribociclibIBA 08/2023 - 01/2018
2	Imatinib Mesylate (Gleevec)FDA Link 01/2023 - 03/2007
2	Phosphotransferases (Kinase)IBA 01/2023 - 12/2006
2	CreatinineIBA 11/2022 - 01/2021
2	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 12/2006
2	rucaparibIBA 01/2021 - 12/2017
2	Capecitabine (Xeloda)FDA Link 01/2021 - 09/2016
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021 - 01/2018
2	Letrozole (Femara)FDA LinkGeneric 01/2020 - 11/2015
2	palbociclibIBA 01/2020 - 11/2015
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 08/2017 - 06/2015
2	Anaplastic Lymphoma KinaseIBA 11/2015 - 06/2015
2	pertuzumabIBA 11/2014 - 09/2013
2	Sunitinib (Sutent)FDA Link 01/2012 - 03/2007
1	talazoparibIBA 03/2024
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024
1	elacestrantIBA 02/2024
1	Estrogen Receptor alphaIBA 02/2024
1	abirateroneIBA 12/2023
1	mirvetuximab soravtansineIBA 10/2023
1	Immunoconjugates (Immunoconjugate)IBA 10/2023
1	Folic Acid (Vitamin M)FDA LinkGeneric 10/2023

Therapy/Procedure

33	Therapeutics 03/2024 - 01/2010
23	Drug Therapy (Chemotherapy) 03/2024 - 01/2010
8	Castration 03/2024 - 12/2013
4	Neoadjuvant Therapy 10/2023 - 07/2014
1	Nephrectomy 03/2024
1	Stents 10/2023
1	Endovascular Procedures 10/2023